In last trading session, Biocept, Inc. (NASDAQ:BIOC) saw 58,440,272 shares changing hands with its beta currently measuring 0.66. Company’s recent per share price level of $0.87 trading at $0 or -8.58% at ring of the bell on the day assigns it a market valuation of $113.86 Million. That closing price of BIOC’s stock is at a discount of -34.48% from its 52-week high price of $1.17 and is indicating a premium of 75.86% from its 52-week low price of $0.21. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 66.22 Million shares which gives us an average trading volume of 25.06 Million if we extend that period to 3-months.
For Biocept, Inc. (BIOC), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 2. Splitting up the data highlights that, out of 2 analysts covering the stock, none rated the stock as a Sell while none recommended an Overweight rating for the stock. None suggested the stock as a Hold whereas 2 see the stock as a Buy. None analyst(s) advised it as an Underweight. The company is expected to be making an EPS of $0 in the current quarter.
Biocept, Inc. (NASDAQ:BIOC) trade information
In the face of being in the red today for losing -8.58%, in the last five days BIOC remained trading in the green while hitting it’s week-highest on Thursday, Jun 18 when the stock touched $0.978 price level, adding 11.2% to its value on the day. Biocept, Inc.’s shares saw a change of 203.67% in year-to-date performance and have moved 56.77% in past 5-day. Biocept, Inc. (NASDAQ:BIOC) showed a performance of 122.12% in past 30-days. Number of shares sold short was 1.56 Million shares which calculate 0.06 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of $1.53 to the stock, which implies a rise of 75.86% to its current value. Analysts have been projecting $1 as a low price target for the stock while placing it at a high target of $2.06. It follows that stock’s current price would jump +136.78% in reaching the projected high whereas dropping to the targeted low would mean a loss of 14.94% for stock’s current value.
Biocept, Inc. (BIOC) estimates and forecasts
1 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of $1.45 Million for the same. And 2 analysts are in estimates of company making revenue of $1.3 Million in the next quarter that will end in June 01, 2020. Company posted $1.02 Million and $1.19 Million of sales in current and next quarters respectively a year earlier. Analysts are expecting this quarter sales to grow by 41.3% while estimating it to be 9.2% for the next quarter.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 67.9% during past 5 years. In 2020, company’s earnings growth rate is likely to be around 86.4% while estimates for its earnings growth in next 5 years are of 40%